Acasti pharma announces positive results for pharmacokinetic bridging study, with intravenous gtx-104 meeting all endpoints

Bioavailability of iv gtx-104 compared favorably with the oral formulation of nimodipine, and no serious adverse events observed for gtx-104

ACST Ratings Summary

ACST Quant Ranking